SystImmune expands its iza-bren programme again
Relapsed biliary tract cancer, and ASCO, beckon.
AbbVie takes pivekimab pivotal
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
AACR 2026 – Qilu challenges Torl in Claudin6
The company’s conjugate QLS5132 has produced intriguing, but early results.
SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
Gilead buys what it tried with Tubulis
A $3.15bn deal follows a December 2024 option agreement.
